Atle Fund Management AB Has $9.84 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Atle Fund Management AB increased its stake in Thermo Fisher Scientific by 6.2%, now holding 24,266 shares valued at approximately $9.8 million, making it the 9th largest position in their portfolio.
• Thermo Fisher reported a second-quarter EPS of $5.36, exceeding analysts' expectations, with revenue of $10.86 billion and a net margin of 15.24%.
• The company declared a quarterly dividend of $0.43, with a 0.4% dividend yield, set to be paid on October 15th to shareholders of record from September 15th.

Atle Fund Management AB increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 6.2% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 24,266 shares of the medical research company's stock after buying an additional 1,409 shares during the quarter. Thermo Fisher Scientific accounts for approximately 4.2% of Atle Fund Management AB's holdings, making the stock its 9th largest holding. Atle Fund Management AB's holdings in Thermo Fisher Scientific were worth $9,839,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Mondrian Investment Partners LTD boosted its holdings in shares of Thermo Fisher Scientific by 146.1% during the 1st quarter. Mondrian Investment Partners LTD now owns 214,506 shares of the medical research company's stock worth $106,738,000 after buying an additional 127,357 shares during the period. Foresight Group Ltd Liability Partnership boosted its stake in shares of Thermo Fisher Scientific by 3,242.7% in the 1st quarter. Foresight Group Ltd Liability Partnership now owns 58,497 shares of the medical research company's stock valued at $29,113,000 after purchasing an additional 56,747 shares during the last quarter. Advisors Capital Management LLC boosted its stake in Thermo Fisher Scientific by 6.7% during the first quarter. Advisors Capital Management LLC now owns 127,011 shares of the medical research company's stock worth $63,201,000 after acquiring an additional 7,967 shares in the last quarter. Ilmarinen Mutual Pension Insurance Co lifted its stake in shares of Thermo Fisher Scientific by 5.3% in the first quarter. Ilmarinen Mutual Pension Insurance Co now owns 67,300 shares of the medical research company's stock valued at $33,488,000 after buying an additional 3,400 shares in the last quarter. Finally, GAMMA Investing LLC raised its holdings in shares of Thermo Fisher Scientific by 22.0% in the first quarter. GAMMA Investing LLC now owns 4,862 shares of the medical research company's stock valued at $2,419,000 after purchasing an additional 877 shares during the last quarter. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

NYSE:TMO traded down $1.08 during mid-day trading on Friday, hitting $480.02. 4,241,401 shares of the company's stock traded hands, compared to its average volume of 1,557,193. The firm has a 50 day moving average of $472.01 and a two-hundred day moving average of $448.95. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $623.77. The firm has a market capitalization of $181.26 billion, a price-to-earnings ratio of 27.76, a price-to-earnings-growth ratio of 2.56 and a beta of 0.75. The company has a current ratio of 1.93, a quick ratio of 1.50 and a debt-to-equity ratio of 0.65.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating the consensus estimate of $5.22 by $0.14. The company had revenue of $10.86 billion during the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a return on equity of 16.82% and a net margin of 15.24%.The business's revenue for the quarter was up 2.9% on a year-over-year basis. During the same period last year, the firm earned $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, equities analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 9.95%.

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 400 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $479.98, for a total value of $191,992.00. Following the sale, the executive vice president owned 22,367 shares of the company's stock, valued at approximately $10,735,712.66. The trade was a 1.76% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CAO Joseph R. Holmes sold 385 shares of the business's stock in a transaction on Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the sale, the chief accounting officer directly owned 2,319 shares in the company, valued at $1,142,408.97. The trade was a 14.24% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 30,066 shares of company stock worth $14,182,963. Company insiders own 0.33% of the company's stock.

Wall Street Analyst Weigh In

TMO has been the topic of several research reports. Barclays raised shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $490.00 to $550.00 in a research report on Thursday, September 11th. Wall Street Zen cut shares of Thermo Fisher Scientific from a "buy" rating to a "hold" rating in a research note on Sunday, September 7th. Hsbc Global Res cut shares of Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a research report on Thursday, July 24th. Wells Fargo & Company decreased their price target on shares of Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating for the company in a research note on Thursday, July 24th. Finally, HSBC restated a "hold" rating and set a $510.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 24th. Sixteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company's stock. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of "Moderate Buy" and an average price target of $588.35.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.